| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ML-148 targets 15-hydroxy prostaglandin dehydrogenase (15-PGDH), the key enzyme responsible for the inactivation of prostaglandins. By inhibiting 15-PGDH, ML-148 increases prostaglandin levels and modulates prostaglandin signaling pathways.
|
|---|---|
| ln Vitro |
ML148 (compound 13) has selectivity IC50s of 56, 36000, >57500, and >57500 nM for 15-PGDH, ALDH1A1, HADH2, and HSD17β4, respectively [1]. At a dose of 10 nM, ML148 (10, 20 nM) decreases the apparent Km by half and the Vmax by 25% [1].
In vitro, ML-148 is a potent and selective 15-PGDH inhibitor with an IC₅₀ of 56 nM. It demonstrates selectivity for 15-PGDH when profiled across a panel of related dehydrogenase or reductase enzymes. It can be used in studies about prostaglandin-signaling pathways. |
| ln Vivo |
In vivo data for ML-148 are limited in the available literature. As a 15-PGDH inhibitor, it may have potential for research in prostaglandin-related conditions. Further in vivo studies are needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
ML-148's 15-PGDH inhibition activity can be characterized using biochemical assays with purified 15-PGDH enzyme. The compound inhibits 15-PGDH with an IC₅₀ of 56 nM. Selectivity against a panel of related dehydrogenases or reductases can be assessed.
|
| Cell Assay |
In vitro cell experiments with ML-148 involve treating cells with the compound and measuring 15-PGDH activity and prostaglandin levels. The compound's effects on prostaglandin signaling pathways can be assessed.
|
| Animal Protocol |
In vivo animal studies with ML-148 have not been extensively reported in the available literature. The compound is primarily used for in vitro research. Further studies are needed to evaluate its in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to ML-148 are limited in the available literature. As a small molecule with a molecular weight of 319.40, the compound is expected to have reasonable bioavailability. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
ML-148 is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices.
|
| References | |
| Additional Infomation |
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methyl ketone is a member of the benzimidazole class of compounds.
ML-148 is a potent and selective 15-PGDH inhibitor with an IC₅₀ of 56 nM. It demonstrates selectivity for 15-PGDH when profiled across a panel of related enzymes. It has a molecular formula of C₂₀H₂₁N₃O and a molecular weight of 319.40. |
| Molecular Formula |
C20H21N3O
|
|---|---|
| Molecular Weight |
319.400244474411
|
| Exact Mass |
319.168
|
| Elemental Analysis |
C, 75.21; H, 6.63; N, 13.16; O, 5.01
|
| CAS # |
451496-96-1
|
| PubChem CID |
3243760
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
543.4±52.0 °C at 760 mmHg
|
| Flash Point |
282.5±30.7 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.651
|
| LogP |
3.31
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
448
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=CC2=C(C=1)N=CN2C1C=CC=C(C)C=1)N1CCCCC1
|
| InChi Key |
YQNOQZALLOQMPY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21N3O/c1-15-6-5-7-17(12-15)23-14-21-18-13-16(8-9-19(18)23)20(24)22-10-3-2-4-11-22/h5-9,12-14H,2-4,10-11H2,1H3
|
| Chemical Name |
[1-(3-methylphenyl)benzimidazol-5-yl]-piperidin-1-ylmethanone
|
| Synonyms |
ML-148; ML148; ML148; CID-3243760; CID3243760; CID 3243760;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~156.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1309 mL | 15.6544 mL | 31.3087 mL | |
| 5 mM | 0.6262 mL | 3.1309 mL | 6.2617 mL | |
| 10 mM | 0.3131 mL | 1.5654 mL | 3.1309 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
